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osting by EAbstract The objective of this research was to develop a kinetic spectrophotometric method for
determination of moxiﬂoxacine (MOXF) in pure form and pharmaceutical formulations. The
method was based on the formation of a colored N-vinyl chlorobenzoquinone derivative of MOXF
by its reaction with 2,3,5,6-tetrachloro-1,4-benzoquinone in presence of acetaldehyde.
The formation of the colored product was monitored spectrophotometrically by measuring the
absorbance at 652 nm. Factors affecting the reaction were studied and optimized. The stoichiome-
try of the reaction was determined, and the reaction pathway was postulated. The activation energy
of the reaction was calculated and found to be 6.65 kJ mol1. Under the optimized conditions, the
initial rate and ﬁxed time (at 5 min) methods were utilized for constructing the calibration graphs.
The graphs were linear in concentration ranges 5–100 and 15–150 lg ml1 with limit of detection of
2.0 and 5.0 lg ml1 for the initial rate and ﬁxed time methods, respectively. The analytical perfor-
mance for both methods was fully validated, and the results were satisfactory. No interference was
observed from the excipients that are commonly present in the pharmaceutical formulations. The
proposed method was successfully applied to the determination of MOXF in its pharmaceutical for-
mulations. The label claim percentages were 101.25 ± 0.73% and 100.92 ± 0.65% for the initial
rate and ﬁxed time method, respectively. Statistical comparison of the results with those obtained
by a reference spectrophotometric method showed excellent agreement between the accuracy and
precision of the two methods. The proposed method has great value in its application to the analysis
of MOXF in quality control laboratories.
ª 2009 King Saud University. All rights reserved.m
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lsevier1. Introduction
Moxiﬂoxacin (MOXF) {1-cyclopropyl-7-[2,8-diazobicyclo
(4.3.0) nonane]-6-ﬂuoro-8-methoxy-1,4-dihydro-4-oxo-3-quin-
olone carboxylic acid} is a new 8-methoxyquinolone derivative
of ﬂuoroquinolones with enhanced activity in vitro against
80 M.A. SultanGram-positive bacteria and maintenance of activity against
Gram-negative bacteria (Balfour and Lamb, 2000; Vishwana-
than et al., 2002; Biedenbach et al., 1998). The drug is rapidly
absorbed, reaching maximum plasma concentrations between
1 and 4 h after oral administration; its half life of 11–15 h
allows a daily administration (Biedenbach et al., 1998).
Moxiﬂoxacin (MOXF) is administered to patients in
400 mg daily doses, being that the ﬁnal concentrations in ser-
um and urine for the treated patients are of 2.00–5.00 and
30.00–60.00 lg ml1, respectively (Wise et al., 1999). MOXF
is prescribed for the bacterial infections of the respiratory
tract including sinusitis, community acquired pneumonia and
acute exacerbation of chronic bronchitis (Muijsers and Jarvis,
2002). Due to clinical advantages of MOXF, there has been in-
crease in number of MOXF formulations in market in recent
past.
No ofﬁcial method for determination of MOXF in phar-
maceutical products is described in the pharmacopoeia. A
survey of literature revealed that MOXF has been deter-
mined in biological ﬂuids or pharmaceutical products by:
high-performance liquid chromatography (HPLC) (Vishwa-
nathan et al., 2002; Chan et al., 2006; Uiu, 2007; Kumar
and Ramachandran, in press), voltammetry (Trindade
et al., 2005), capillary electrophoresis with laser-induced ﬂuo-
rescence (Faria et al., 2006), atomic absorption (Al-Ghan-
nam, 2008), spectroﬂuorometry (Ocana et al., 2000) and
spectrophotometry (Al-Ghannam, 2008; Motwani et al.,
2007; Venugopal and Saha, 2005; Patel et al., 2005; Ilango
et al., 2006; Jane et al., 2006).
The chromatographic, voltammetric, electrophoretic and
atomic absorption methods utilized delicated and/or expensive
instruments that are not available in most quality control lab-
oratories. Spectrophotometric technique is the most widely
used in pharmaceutical analysis (Darwish et al., 2008, 2009).
The widespread of spectrophotometric methods is attributed
to their inherent simplicity, economic advantages and wide
availability in most quality control laboratories.
However, few spectrophotometric methods were reported
for determination of MOXF in its pharmaceutical dosage
forms (Al-Ghannam, 2008; Motwani et al., 2007; Venugopal
and Saha, 2005; Patel et al., 2005; Ilango et al., 2006; Jane
et al., 2006). These methods were associated with some major
drawbacks such as decrease selectivity due to measurement in
ultraviolet region (Venugopal and Saha, 2005) and/or de-
creased simplicity of the assay procedure (e.g. tedious precipi-
tation (Al-Ghannam, 2008)).
For these reasons, it was worthwhile to develop a new sim-
ple and selective spectrophotometric method for the determi-
nation of MOXF in its pharmaceutical dosage forms.
Kinetic spectrophotometric methods are becoming of great
interest in the pharmaceutical analysis (Chamjangali et al.,
2006; Darwish, 2005; Rahman et al., 2006). The application
of these methods offers some speciﬁc advantages such as im-
proved selectivity due to the measurement of the evolution
of the absorbance with the reaction time. As well, it proved
the avoiding of the interference of the colored and/or turbidity
background of the samples, and possibility the interference of
the other active ingredients present in the combined pharma-
ceutical formulations.
No attempts have been reported for the kinetic spectropho-
tometric determination of MOXF. The present study de-
scribes, for the ﬁrst time, the development and validation ofa selective and simple kinetic spectrophotometric method for
the determination of MOXF.
The proposed method was based on the formation of a col-
ored N-vinyl chlorobenzoquinone derivative of MOXF by its
reaction with 2,3,5,6-tetrachloro-1,4-benzoquinone (TCBQ)
in presence of acetaldehyde. The development of the color
was monitored spectrophotometrically at its maximum
absorption peak. The initial rate and ﬁxed time methods, after
their full optimization and validation, were adopted for the
determination of MOXF in its pharmaceutical dosage forms.2. Experimental
2.1. Apparatus
Double beam V-530 (JASCO Co. Ltd., Kyoto, Japan) ultra-
violet–visible spectrophotometer with matched 1-cm quartz
cells was used for all the spectrophotometric measurements.
2.2. Chemicals and dosage forms
Pharmaceutical grade moxiﬂoxacin (MOXF) base was a kind
gift from Bayer (Riyadh, KSA), its purity was 100.2 ± 0.65.
Acetaldehyde (ACD; Sigma Chemical Co., St. Louis, USA)
was 70% (v/v), prepared in methanol.
2,3,5,6-Tetrachloro-1,4-benzoquinone (TCBQ; Sigma
Chemical Co., USA) was 2 · 102 mol l1, freshly prepared
in dioxane. All solvents and other chemicals used through this
study were of analytical grade.
Avalox tablets (Bayer AG.Germany/Allemagne) are
labeled to contain 400 mg MOXF per tablet (batch number,
BXFOCJI).2.3. Preparation of standard and sample solutions
2.3.1. Preparation of stock standard solution
Into a 50-ml calibrated ﬂask, an accurately weighed amount
(100 mg) of MOXF was dissolved in 40 ml of methanol. For
complete dissolution of MOXF, the solution was sonicated
for 5 min. The resulting solution was completed to volume
with the same solvent. This stock solution (2 mg ml1) was di-
luted with butanol to obtain working concentrations in the
range of 50–1500 g ml1.2.3.2. Preparation of dosage forms sample solution
Twenty tablets were weighed and ﬁnely powdered. A quantity
of the mixed powder equivalent to 100 mg of MOXF was
transferred into a 50-ml calibrated ﬂask, dissolved in 25 ml
of methanol, swirled and sonicated for 5 min, completed to
volume with the same solvent, shaken well for 10 min, and ﬁl-
tered. The ﬁrst portion of the ﬁltrate was rejected, and 25 ml of
the ﬁltrate was diluted with butanol to obtain working concen-
trations in the range of 50–1500 lg ml1.2.4. General analytical procedures and data treatment
One milliliter of the standard or sample solution (50–
1500 lg ml1) was transferred into 10-ml calibrated ﬂasks.
One milliliter of the ACD solution (70%, v/v in methanol)
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reaction mixture was mixed and completed to volume with
butanol. After dilution and mixing, the reaction mixture was
immediately transferred to a spectrophotometric cell and the
absorbance was recorded (at 652 nm) as a function of time
against reagent blank treated similarly.
The kinetic data that has been recorded were transformed
to the Slide Write Plus software, version 5.011 (Advanced
Graphics Software, Inc., CA, USA) for curve ﬁtting, regres-
sion analysis, and statistical calculations. The initial rate (K)
of the reaction at different concentrations was obtained from
the slope of the tangent to the absorbance–time curve. The cal-
ibration curve was constructed by plotting the logarithm of the
initial rate (log K) of reaction versus logarithm of the concen-
tration (log C) of MOXF. Alternatively, the calibration curve
was constructed by plotting the absorbance measured after a
ﬁxed time of 5 min.
2.5. Determination of molar ratio of the reactions
2.5.1. For MOXI with ACD
The limiting logarithmic method (Rose, 1964) was employed.
Two sets of experiments were carried out employing the general
recommended procedures described above. The ﬁrst set of
experiments were carried using increasing ACD concentrations
(3 · 102–1.8 · 101 M) at a ﬁxed MOXF concentration
(1.32 · 104 M). The second set of experiments were carried
using increasing MOXF concentrations (2.54 · 105–2.54 ·
104 M) at ﬁxed ACD concentration (0.2 M). The logarithms
of the obtained absorbances were plotted as function of the log-
arithms of the ACD and MOXF concentration in the ﬁrst and
second sets of experiments, respectively. The slopes of the ﬁtting
lines in both sets of experiments were calculated.
2.5.2. For MOXI with TCBQ
The limiting logarithmic method (Rose, 1964) was employed.
Two sets of experiments were carried out employing the general
recommended procedures described above. The ﬁrst set of
experiments were carried using increasing TCBQ concentra-
tions (1.3 · 104–2.0 · 103 M) at a ﬁxedMOXF concentrationFigure 1 Absorption spectra of 6 lg ml1 of MOXF (1) and the
reaction product (2) of MOXF (50 lg ml1) with TCBQ (2 · 103)
in presence of ACD (7%, v/v).(1.32 · 104 M). The second set of experiments were carried
using increasing MOXF concentrations (2.54 · 105–2.54 ·
104 M) at ﬁxed TCBQ concentration (2.0 · 103 M). The log-
arithms of the obtained absorbances were plotted as function of
the logarithms of the TCBQ and MOXF concentration in the
ﬁrst and second sets of experiments, respectively. The slopes
of the ﬁtting lines in both sets of experiments were calculated.
3. Results and discussion
3.1. Involved reaction and absorption spectra
The reaction involved in the present study was based on the for-
mation of a colored N-vinyl chlorobenzoquinone derivative of
MOXF by its reaction with TCBQ in presence of ACD. The
formation of this colored product was monitored spectrophoto-
metrically at its maximum absorption peak (652 nm). The
absorption spectrum for the reaction product is given in Fig. 1.
The following sections describe the optimization of different
factors affecting the reaction, kinetics, and the use of the opti-
mized conditions in the development of the assay procedures.
3.2. Optimization of reaction conditions
The factors affecting reaction conditions (concentrations of
ACD and TCBQ reagents, temperature, and the diluting sol-
vent) were studied by altering each variable in turn while keep-
ing the others constant. The intensity of the developed color
was recorded as a function of the concentrations of ACD
and TCBQ reagent. It was found that the color intensity was
dependent on the concentration of both reagents (Fig. 2).
The highest color intensity was attained when the concentra-
tions of ACD and TCBQ in the ﬁnal reaction solution were
7% (v/v) and 2 · 103 M, respectively; these concentrations
were used in all the subsequent experiments. The reaction
was carried out at room temperature (25 ± 5 C) and at ele-
vated temperatures. It was found that the color intensity de-
creased signiﬁcantly when the reaction temperature increased
(Fig. 3). This was probably attributed to the instability of
the colored product at elevated temperature. Therefore, the
further experiments were carried out at room temperature.Figure 2 Effect of ACD (s) and TCBQ (d) concentrations on
the absorption intensity of their reaction with MOXF
(50 lg ml1).
Figure 3 Effect of temperature on the reaction of MOXF
(50 lg ml1) with TCBQ (2 · 103) in presence of ACD (7%, v/v).
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82 M.A. SultanIn order to select the most appropriate solvent for dilution,
different solvents were tested: methanol, ethanol, propan-2-ol,
butanol, acetonitrile, acetone, and dimethylformamide. The
highest color intensity was attained when butanol was used
as a diluting solvent; therefore it was selected for the further
investigations.
3.3. Stoichiometry, mechanism, and kinetics of the reaction
The stoichiometry of the reaction between MOXF and each of
ACD and TCBQ was investigated by limiting logarithmic
method (Rose, 1964). The time-dependence of the reaction be-
tweenMOXF and ACDwas ﬁrst investigated, and it was found
that the reaction proceeds instantaneously (data not shown).
Upon studying the stoichiometric ratio of MOXF:ACD using
a ﬁxed concentration of MOXF (1.32 · 104 M), two straight
lines with comparable slopes were obtained indicating that
1:1 ratio was involved in the reaction of MOXF with ACD
(Fig. 4). Upon studying the ratio of MOXF:TCBQ, the slope
of the line that was generated using varying [MOXF] with ﬁxed
equimolar concentrations of ACD and TCBQ was 2-folds of
the slopes of the other lines. This indicated that the ratio of
MOXF:TCBQ was 2:1 which was conﬁrmed also by Job’s
method (Job, 1936). Based on these ratios, the reaction path-
way was postulated to proceed as shown in Fig. 5. MOXF,
via its piprazinyl NH, reacted with ACD and produced theFigure 4 Limiting logarithmic plots for molar reactivity of MOXF with ACD and TCBQ. log C and log A are the logarithm of the
concentration and absorbance, respectively. The ﬁrst line (a): log A versus log [MOXF]; the second line (b): log A versus log [TCBQ]; the
third line (c): log A versus [ACD].
Figure 6 Absorbance–time curves for the reaction of varying
concentrations of MOXF (-m-, 0.32), (-e-, 0.75), (-r-, 1.50), (-s-,
2.00), (-d-, 2.54) (M · 104) (with TCBQ (2 · 103 M) in presence
of ACD (7%, v/v).
Figure 7 Linear plot for log C versus log K for the kinetic
reaction of MOXF with TCBQ (2 · 103 M) in presence of ACD
(7%, v/v) and C is [MOXF], (0.25 · 104–2.54 · 104 M); K is the
reaction rate (s1).
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with TCBQ and produced the colored N-vinyl chlorobenzoqui-
none derivative of MOXF.
Under the optimum conditions, the absorbance–time
curves for the reaction of varying MOXF concentrations
(0.32 · 104–2.54 · 104 M) with a ﬁxed concentration of
TCBQ (2 · 103 M) in presence of ACD (7%, v/v) were
generated (Fig. 6). The initial reaction rates (K) were deter-
mined from the slopes of these curves. The logarithms of the
reaction rate (log K) were plotted as a function of logarithms
of MOXF concentrations (log C) (Fig. 7). The regression anal-
ysis for the values was performed by ﬁtting the data to the fol-
lowing equation:
logK ¼ log k0 þ n logC
where K is reaction rate, k0 is the rate constant, C is the molar
concentration of MOXF, and n (slope of the regression line) is
the order of the reaction. A straight line with slope values of
1.164 (1) was obtained conﬁrming that the reaction was ﬁrst
order. However under the optimized reaction conditions, the
concentrations of ACD and TCBQ were in much more excess
than that of MOXF in the reaction solution. Therefore, the
reaction was regarded as a pseudo-ﬁrst order reaction. Since
the reaction between MOXF and ACD was instantaneous,the rate- limiting step in the overall reaction was the condensa-
tion of the N-vinyl-MOXF with TCBQ reagent.
3.4. The apparent rate constant and activation energy
The absorbance–time curves at different temperatures (20–
40 C) were generated using ﬁxed concentration of MOXF
(1.0 · 104 mol l1), ACD (7%, v/v), and TCBQ (2 ·
103 mol l1). From these curves the apparent rate constants
were calculated. The activation energy, deﬁned as the mini-
mum kinetic energy that a molecule possess in order to under-
go a reaction, was determined using Arrhenius equation
(Martin et al., 1983):
log k ¼ logF Ea=2:303RT
where k is the apparent rate constant, F is the frequency factor,
Ea is the activation energy, T is the absolute temperature (C+
273), and R is the gas constant (1.987 calories deg1 mol1).
The values of log k were plotted as a function of 1/T. Straight
line with slope value of 0.4444 (=Ea/2.303R) was obtained.
From these data, the activation energy was calculated and
found to be 6.65 kJ mol1. This low activation energy explained
that the proposed reaction could be easily takes place under
mild conditions, and ACD–TCBQ combination could be used
as useful analytical reagents in the spectrophotometric determi-
nation of MOXF.
3.5. Quantitation methods
3.5.1. Initial rate method
The initial rate of the reaction for MOXF followed a pseudo-
ﬁrst order and were found to obey the following equation:
K ¼ DA=Dt ¼ KnCn
where K is the reaction rate, A is the absorbance, t is the mea-
suring time, Kn is the pseudo-ﬁrst order rate constant, C is the
molar concentration of MOXF and n is the order of the reac-
tion. The logarithmic form of the above equation is written as
follows:
logK ¼ logDA=Dt ¼ logKn þ n logC
Regression analysis, using the method of least square was per-
formed for the data. The value of n (slope) was 1.16 (1) in the
regression equation, conﬁrmed that the reaction was ﬁrst order
with respect to MOXF concentration, the relation is linear in
the range of 5–100 lg ml1, with good correlation coefﬁcient
(0.9992). The limit of detection (LOD) and limit of
quantiﬁcation (LOQ) were calculated and found to be 2.0
and 6.0 lg ml1, respectively. These low values conﬁrmed the
high sensitivity of the method and consequently its capability
to determine low amounts of MOXF.
3.5.2. Fixed time method
In this method, the absorbance of the reaction solution
containing varying amounts of MOXF was measured at a
pre-selected ﬁxed time. Calibration plots of absorbance versus
the concentrations of MOXF were established at ﬁxed periods
of time for the reaction. The regression equations, coefﬁcients
of correlation, and limits of detection are given in Table 1.
Obviously, the LOD values decreased as the measuring ﬁxed
time increased. The widest linear ranges were obtained at 2
Table 1 Analytical parameters for the proposed ﬁxed time spectrophotometric method for determination of MOXF.
Reaction time
(min)
Linear range
(lg ml1)
Intercept Standard deviation
of intercept
Slope Standard deviation
of slope
Correlation
coeﬃcient
LOD
(lg ml1)
LOQ
(lg ml1)
2 20–200 0.0211 0.0134 0.0049 0.000362 0.9967 7.0 21.0
5 15–150 0.0038 0.0061 0.0077 0.000205 0.9996 5.0 15.0
10 10–130 0.0041 0.0093 0.0087 0.000331 0.9995 2.8 8.5
15 8–115 0.0035 0.0094 0.0108 0.000190 0.9995 2.5 7.6
20 6–100 0.0029 0.0065 0.0115 0.000221 0.9997 2.5 6.8
25 6–75 0.0006 0.0081 0.0120 0.000409 0.9996 2.0 6.0
30 6–80 0.0002 0.0055 0.0125 0.000158 0.9997 1.5 4.8
Table 2 Accuracy and precision for the initial rate and ﬁxed-time spectrophotometric methods for determination of MOXF.
Concentration (lg ml1) Recovery (± RSD)a
Initial rate method Fixed time method
Intra-assay Inter-assay Intra-assay Inter-assay
20 100.2 ± 1.87 100.6 ± 1.68 99.9 ± 0.98 99.3 ± 0.15
50 101.6 ± 1.04 98.9 ± 1.43 99.7 ± 0.38 100.2 ± 0.08
90 100.1 ± 0.61 99.5 ± 0.82 100.0 ± 0.15 100.0 ± 0.02
a Values are the mean of at least three determinations.
Table 3 Results of analysis of MOXF tablets by the proposed methods and comparison method.a
Dosage form Proposed method Comparison methoda
Initial rate method Fixed time method
Avalox tablets, 400 mg MOXF/tablet
Label claim* (% ±RSD) 101.25 ± 0.73 100.92 ± 0.65 101.86 ± 0.53
N 4 4 4
Variance 0.53 0.42 0.28
F-test 1.89 1.40 (9.28)**
t-test 1.36 2.23 (2.36)**
a Motwani et al. (2007).
* Values are mean ± RSD of four determinations.
** Values in parenthesis are tabulated values at p= (0.05).
84 M.A. Sultanand 5 min, however poor linearity was obtained at 2 min, as
the correlation coefﬁcient was low. According to the ICH
guidelines for validation of analytical procedures (Interna-
tional Conference on Harmonization, 1995), the LOD is not
required to be part of the validation. Therefore, on the
basis of wider concentration range and less time of analysis,
the ﬁxed time of 5 min was recommended for analytical
procedure.
3.6. Validation of the proposed methods
3.6.1. Accuracy and precision
The accuracy and precision of the proposed kinetic spectro-
photometric method were determined at three concentration
levels (20, 50, and 90 lg ml1) of MOXF by analyzing ﬁve
replicate samples of each concentration by both the initial
rate and ﬁxed time methods. The relative standard devia-
tions (RSD) for the results did not exceed 2% (Table 2),
proving the high reproducibility of the results and the precision
of the method. This good level of precision was suitable forquality control analysis of MOXF in its pharmaceutical
tablets.
3.6.2. Application of the proposed methods
It is evident from the results obtained previously that the pro-
posed initial rate and ﬁxed time methods of the proposed ki-
netic spectrophotometric method for determination of
MOXF gave satisfactory results with the analysis of MOXF
in bulk. The methods were applied on the analysis of commer-
cial MOXF tablets dosage form. The concentration of MOXF
was computed from its corresponding regression equations.
The results of the proposed methods (initial rate or ﬁxed time)
were statistically compared with those of the reported method
(Motwani et al., 2007), in respect to the accuracy and
precision. The obtained mean recoveries and relative standard
deviations of the labeled amounts were 101.25 ± 0.73%
and 100.9 ± 0.65% for the initial rate and the ﬁxed time meth-
ods, respectively (Table 3). In the t- and F-tests, no signiﬁcant
differences were found between the calculated and theoretical
values of both the proposed and the reported methods at
Table 4 The analytical ﬁgures of merit of the previously-mentioned spectrophotometric methods.
Method/reagent Reaction conditions kmax (nm) Beer’s range (lg ml
1) LOD (lg ml1) Ref.
Proposed initial rate 25 C/10 min 655 5–100 2.0 This work
Proposed ﬁxed time 25 C/5 min 655 15–150 5.0 This work
UV-spectrophotometry
In 0.1 N hydrochloric acid pH 1.2 296 1–12 0.0402 Motwani et al. (2007)
In phosphate buﬀer pH 7.4 289 1–14 0.1217 Motwani et al. (2007)
Formation of ion-pair associates
Ammonium reineckate* 5 · 103 M ammonium
reineckate + 0.01 M HCl
525 100–1100 45 Al-Ghannam (2008)
* The ion pair associate, as precipitate, was dissolved in acetone before measuring.
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accuracy in the analysis of MOXF in its dosage forms. It is
worth noting that all the proposed kinetic spectrophotometric
methods were performed in the visible region away from the
UV-absorption region of the UV-absorbing interfering
excipient materials that might be co-extracted from the
MOXF-containing tablets.
3.7. Comparison of the proposed methods with the reported
spectrophotometric methods
The proposed methods, because they involve measurements in
visible region, are more selective than the previously reported
spectrophotometric method that involved measurements in
the ultraviolet region (Motwani et al., 2007; Venugopal and
Saha, 2005). As well, the proposed methods are superior to
the reported methods that were based on the ion-pair associ-
ates (Al-Ghannam, 2008), as the proposed methods do not re-
quire elaborate treatment of the samples, careful adjustment of
the critical optimum pH of the reaction medium, and/or te-
dious liquid-liquid extraction for the chromophores. Further-
more, the proposed methods have wider linear dynamic
ranges than that of many of the reported methods (Table 4).
These advantages encourage the application of the proposed
methods in routine analysis of MOXF in quality control labo-
ratories, as alternatives for the existing methods.4. Conclusion
The present study described, for the ﬁrst time, a selective and
simple kinetic spectrophotometric method for the determina-
tion of MOXF in its tablet. The proposed initial rate and ﬁxed
time methods can be easily applied as they do not require elab-
orate treatment of the samples and/or tedious procedures for
extraction of the chromophore. As well, both methods are sen-
sitive enough for analysis of lower amounts of MOXF. Fur-
thermore, the proposed methods do not require expensive
instruments and/or critical analytical reagents. These advanta-
ges give the proposed methods a great value and encourage its
application to the analysis of MOXF in quality control
laboratories.References
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